Nisa Investment Advisors
DNLI icon

Nisa Investment Advisors’s Denali Therapeutics DNLI Stock Holding History

Nisa Investment Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.5K Buy
2,424
+975
+67% +$19.4K ﹤0.01% 1695
2025
Q4 		$23.9K Sell
1,449
-34
-2% -$574 ﹤0.01% 1874
2025
Q3 		$21.5K Buy
1,483
+266
+22% +$3.82K ﹤0.01% 1961
2025
Q2 		$17K Sell
1,217
-199
-14% -$2.8K ﹤0.01% 2019
2025
Q1 		$19.3K Sell
1,416
-65,205
-98% -$1.25M ﹤0.01% 1896
2024
Q4 		$1.36M Buy
66,621
+139
+0.2% +$3.56K 0.01% 795
2024
Q3 		$1.94M Buy
66,482
+160
+0.2% +$3.97K 0.01% 686
2024
Q2 		$1.54M Buy
66,322
+193
+0.3% +$3.71K 0.01% 766
2024
Q1 		$1.36M Buy
66,129
+70
+0.1% +$1.32K 0.01% 785
2023
Q4 		$1.42M Buy
66,059
+48,099
+268% +$953K 0.01% 755
2023
Q3 		$371K Buy
17,960
+10
+0.1% +$254 ﹤0.01% 1158
2023
Q2 		$530K Buy
17,950
+192
+1% +$5.4K ﹤0.01% 1060
2023
Q1 		$409K Sell
17,758
-160
-0.9% -$4.4K ﹤0.01% 1122
2022
Q4 		$498K Hold
17,918
– – ﹤0.01% 1118
2022
Q3 		$544K Buy
17,918
+102
+0.6% +$3.32K ﹤0.01% 998
2022
Q2 		$524K Buy
17,816
+15,200
+581% +$398K ﹤0.01% 1038
2022
Q1 		$84K Sell
2,616
-1,235
-32% -$42.5K ﹤0.01% 1682
2021
Q4 		$132K Sell
3,851
-2,295
-37% -$109K ﹤0.01% 1412
2021
Q3 		$310 Sell
6,146
-48
-0.8% -$2.71K ﹤0.01% 1264
2021
Q2 		$486 Sell
6,194
-100
-2% -$6.19K ﹤0.01% 1146
2021
Q1 		$359 Buy
6,294
+450
+8% +$30.1K ﹤0.01% 1268
2020
Q4 		$489K Buy
5,844
+3,254
+126% +$197K ﹤0.01% 1161
2020
Q3 		$93K Buy
2,590
+1,830
+241% +$55.1K ﹤0.01% 1566
2020
Q2 		$18K Buy
760
+300
+65% +$7.05K ﹤0.01% 1796
2020
Q1 		$8K Buy
+460
New +$9.6K ﹤0.01% 1885

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nisa Investment Advisors's DNLI Position: Q1 2026 in Review

Nisa Investment Advisors increased its Denali Therapeutics (DNLI) stake by 67% in Q1 2026, buying an estimated $19.4K and bringing the position to 2,424 shares worth $46.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1695.

Nisa Investment Advisors first reported a position in DNLI in Q1 2020 and has held it in 25 quarters since. The position peaked at $1.94M in Q3 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Nisa Investment Advisors held 2,424 shares of Denali Therapeutics worth $46.5K as of Q1 2026.
  • Nisa Investment Advisors bought 975 Denali Therapeutics shares in Q1 2026, an estimated $19.4K.
  • Denali Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1695 holding.
  • Nisa Investment Advisors first reported a position in Denali Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Nisa Investment Advisors's Denali Therapeutics position peaked at $1.94M in Q3 2024.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.